Skip to main content
SpringerLink
Log in

Bijwerkingen van inhalatiecorticosteroïden: consequenties voor de eerste lijn

  • Artikel
  • Published:
Bijblijven

Samenvatting

Inhalatiecorticosteroïden (ICS) worden zowel voor de behandeling van astma als voor die van COPD gebruikt. Hoewel de behandeling met ICS zeker bij astma vaak effectief is, kunnen de bijwerkingen een negatieve invloed hebben op de therapietrouw en de ziekte-uitkomst. Deze bijdrage geeft een overzicht van de verschillende lokale en systemische bijwerkingen van ICS, hun ontstaanswijze en prevalentie. Daarnaast worden enkele strategieën besproken om de bijwerkingen te identificeren en reduceren.

In de dagelijkse praktijk blijken de bijwerkingen van ICS, hoewel ze vaak voorkomen, echter lang niet altijd besproken te worden. Het is dus van belang openlijk naar bijwerkingen te vragen tijdens het consult. Vervolgens kunnen verschillende strategieën toegepast worden om de bijwerkingen te reduceren, zoals een dosisreductie of het gebruik van een voorzetkamer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatuur

  1. GINA Report, Global Strategy for Asthma Management and Prevention. Ontario: GINA; 2006. NIH Publication No 02-3659. http://www.ginasthma.com, geraadpleegd 4-1-2007.

  2. Gartlehner G, Hansen R, Carson S, Lohr K. Efficacy and safety of inhaled corticosteroids in patients with COPD: A systematic review and meta-analysis of health outcomes. Ann Fam Med 2006;4:253-62.

    Google Scholar 

  3. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55.

    Google Scholar 

  4. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 1997;91 Suppl A:22-8.

    Google Scholar 

  5. Ellepola AN, Samaranayake LP. Inhalational and topical steroids, and oral candidosis: A mini review. Oral Dis 2001;7:211-6.

    Google Scholar 

  6. Akpan A, Morgan R. Oral candidiasis. Postgrad Med J 2002;78:455-9.

    Google Scholar 

  7. Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy 2006;61:518-26.

    Google Scholar 

  8. Williamson IJ, Matusiewicz SP, Brown PH, Greening AP, Crompton GK. Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations. Eur Respir J 1995;8:590-2.

    Google Scholar 

  9. Dubus JC, Marguet C, Deschildre A, Mely L, Le Roux P, Brouard J, et al. Local side-effects of inhaled corticosteroids in asthmatic children: Influence of drug, dose, age, and device. Allergy 2001;56:944-8.

    Google Scholar 

  10. Lavy JA, Wood G, Rubin JS, Harries M. Dysphonia associated with inhaled steroids. J Voice 2000;14:581-8.

    Google Scholar 

  11. Passalacqua G, Albano M, Canonica GW, Bachert C, Van Cauwenberge P, Davies RJ, et al. Inhaled and nasal corticosteroids: Safety aspects. Allergy 2000;55:16-33.

    Google Scholar 

  12. Allen DB, Mullen M, Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol 1994;93:967-76.

    Google Scholar 

  13. Guillot B. Skin reactions to inhaled corticosteroids: Clinical aspects, incidence, avoidance, and management. Am J Clin Dermatol 2000;1:107-11.

    Google Scholar 

  14. Capewell S, Reynolds S, Shuttleworth D, Edwards C, Finlay AY. Purpura and dermal thinning associated with high dose inhaled corticosteroids. Br Med J 1990;300:1548-51.

    Google Scholar 

  15. Vries TW de, Langen-Wouterse JJ, Puijenbroek E van, Duiverman EJ, Jong-van den Berg LT de. Reported adverse drug reactions during the use of inhaled steroids in children with asthma in the Netherlands. Eur J Clin Pharmacol 2006;62:343-6.

    Google Scholar 

  16. Ernst P, Baltzan M, Deschenes J, Suissa S. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J 2006;27:1168-74.

    Google Scholar 

  17. Foster JM, Sonderen E van, Lee AJ, Sanderman R, Dijkstra A, Postma DS, et al. A self-rating scale for patient-perceived side effects of inhaled corticosteroids. Respiratory Research 2006;7:131.

    Google Scholar 

  18. Garbe E, LeLorier J, Boivin JF, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997;277:722-7.

    Google Scholar 

  19. Kargul B, Tanboga I, Ergeneli S, Karakoc F, Dagli E. Inhaler medicament effects on saliva and plaque pH in asthmatic children. J Clin Pediatr Dent 1998;22:137-40.

    Google Scholar 

  20. Gillissen A, Lecheler J. Corticophobia in asthma. Med Klin (Munich) 2003;98:417-22.

    Google Scholar 

  21. Pound P, Britten N, Morgan M, Yardley L, Pope C, Daker-White G, et al. Resisting medicines: A synthesis of qualitative studies of medicine taking. Soc Sci Med 2005;61:133-55.

    Google Scholar 

  22. Canonica GW, Dahl R, Kaliner MA, Valovirta EJ, Baena-Cagnani CE, Blaiss MS. Global asthma physician & patient (GAPP) survey: satisfaction with current asthma medications in Europe – adult findings. Proc Am Thorac Soc 2006;3:1982.

    Google Scholar 

  23. Breekveldt-Postma NS, Gerrits CM, Lammers JW, Raaijmakers JA, Herings RM. Persistence with inhaled corticosteroid therapy in daily practice. Respir Med 2004;98:752-9.

    Google Scholar 

  24. Van Staa TP, Cooper C, Leufkens HG, Lammers JW, Suissa S. The use of inhaled corticosteroids in the United Kingdom and the Netherlands. Respir Med 2003;97:578-85.

    Google Scholar 

  25. Williams LK, Pladevall M, Xi H, Peterson EL, Joseph C, Lafata JE, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol 2004;114:1288-93.

    Google Scholar 

  26. Boulet LP. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest 1998;113:587-92.

    Google Scholar 

  27. Britten N, Stevenson F, Gafaranga J, Barry C, Bradley C. The expression of aversion to medicines in general practice consultations. Soc Sci Med 2004;59:1495-503.

    Google Scholar 

  28. Alvarez-Requejo A, Carvajal A, Begaud B, Moride Y, Vega T, Arias LH. Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol 1998;54:483-8.

    Google Scholar 

  29. Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM, et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: A randomized controlled trial. J Clin Oncol 2004;22:714-24.

    Google Scholar 

  30. Hershey CO, Grant BJB. Controlled trial of a patient-completed history questionnaire: Effects on quality of documentation and patient and physician satisfaction. Am J Med Qual 2002;17:126-35.

    Google Scholar 

  31. Rachelefsky GS, Liao Y, Faruqi R. Impact of inhaled corticosteroid-induced oropharyngeal adverse events: results from a meta-analysis. Ann Allergy Asthma Immunol 2007;98:225-38.

    Google Scholar 

  32. Lundborg M, Wille S, Bjermer L, Tilling B, Lundgren M, Telg G, et al. Maintainance plus reliever budesonide/formoterol compared with a higher maintainance dose of budesonide/formoterol plus formoterol as reliever in asthma: An efficacy and cost-effectiveness study. Curr Med Res Opin 2006;22: 809-21.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. www.bsl.nl/shop/bijblijven-0168-9428.html

    K. Hofman

Authors
  1. K. Hofman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. van der Molen
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

onderzoeker, Disciplinegroep Huisartsgeneeskunde, Universitair Medisch Centrum Groningen.

onderzoeker, Disciplinegroep Huisartsgeneeskunde, Universitair Medisch Centrum Groningen.

hoogleraar Astma en COPD in de huisartsenpraktijk, Disciplinegroep Huisartsgeneeskunde, Universitair Medisch Centrum Groningen, Department of General Practice and Primary Care, University of Aberdeen, Schotland.

Mogelijke belangenverstrengeling: Prof.dr. T. van der Molen heeft voor onderzoek bedragen van meer dan $ 10.000 ontvangen van Altana Pharma, Astra Zeneca, GlaxoSmithKline, Merck Sharp & Dohme, en voor lezingen en adviezen bedragen van minder dan $ 10.000 van Altana Pharma, Astra Zeneca, Boehringer Ingelheim/Pfizer, GlaxoSmithKline. De andere auteurs hebben geen financiële ondersteuning ontvangen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hofman, K., van der Molen, T. Bijwerkingen van inhalatiecorticosteroïden: consequenties voor de eerste lijn. BIJB 23, 12–19 (2007). https://doi.org/10.1007/BF03087607

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03087607

Search

Navigation